Research
Energy balance
Once-weekly subcutaneous semaglutide (2.4 mg) resulted in a mean body weight change of -16.0% compared to -5.7% for placebo at week 68.
Semaglutide can be an effective adjunct treatment for weight management in adults with overweight or obesity.
StrongSupportsmedium confidence
At week 68, the estimated mean body weight change from baseline was -16.0% for semaglutide vs -5.7% for placebo.
Why this rating
Based on a randomized, double-blind, parallel-group, phase 3a study design.
Source
Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
Thomas A. Wadden et al. · JAMA · 2021
rct · n=611Cited 983×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →